Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.

about

Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.

Item

http://www.wikidata.org/entity/Q38655765

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.

@en

type

Item

label

Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.

@en

prefLabel

Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.

@en

P1476

Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.

@en

P2093

Masako Okada

http://www.w3.org/2001/XMLSchema#string

Masaru Enomoto

http://www.w3.org/2001/XMLSchema#string

Mindie H Nguyen

http://www.w3.org/2001/XMLSchema#string

Norifumi Kawada

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B.

Assessment of hepatic fibrosis regression by transient elastography in patients with chronic hepatitis B treated with oral antiviral agents

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.

Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis.

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

P304

1-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17474124.2017.1361822

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28752768

http://www.w3.org/2001/XMLSchema#string